en.Wedoany.com Reported - The sterile fill-finish contract development and manufacturing organization (CDMO) ten23 health announced that it has successfully completed testing of the West Synchrony S1 pre-fillable syringe (PFS) system at its manufacturing facility. The syringe system, globally commercialized by West Pharmaceutical Services, integrates the syringe barrel, plunger, and needle shield into a validated single-vendor system.

ten23 health stated that by evaluating the West Synchrony S1 PFS system early on its fill-finish line, it can help biopharmaceutical customers rapidly deploy it for clinical and early-stage commercialization projects, thereby reducing technical risk and accelerating development timelines. As drug developers face increasing regulatory and technical complexity, achieving early compatibility between the container system and the manufacturing process has become critical.

"We have implemented and tested the West Synchrony S1 pre-fillable syringe system on our equipment, so we are fully capable of supporting partners in achieving operational readiness," said Hanns-Christian Mahler, Chief Enabling Officer of ten23 health. He added: "Early hands-on experience with new container systems is essential for reducing development risk, especially as combination products and home-based administration continue to grow."

The West Synchrony S1 PFS syringe system offers multiple configurations suitable for biologics and vaccines, including staked needle and Luer lock, as well as high-performance NovaPure and FluroTec coated plunger assemblies. ten23 health's initial evaluation focused on manufacturability, compatibility, and process robustness under representative fill-finish conditions.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com